GLP-1 Drugs for ALS: Biologically Plausible but Potentially Harmful — Weight Loss May Worsen Prognosis | Research

The takeaway

Despite compelling neuroprotective rationale, GLP-1 RAs may be harmful in ALS because their weight loss and lean mass reduction effects worsen prognosis in this disease where weight maintenance is protective.

Helpful elsewhere, harmful here?
GLP-1 drugs' signature weight loss effect — beneficial in most diseases — may worsen ALS outcomes where higher BMI predicts better survival

What the researchers found

GLP-1 RAs have compelling neuroprotective rationale for ALS (anti-inflammatory, mitochondrial, anti-excitotoxic) but their weight loss and lean mass reduction effects may worsen ALS prognosis, where higher BMI/weight maintenance is protective.

Why it matters

Rushing to try GLP-1 drugs in ALS based on success in other neurodegenerative diseases could harm patients. This review provides essential safety context.

How the study worked

Narrative review of metabolic impairment in ALS, GLP-1 RA neuroprotective mechanisms, preclinical evidence (heterogeneous), and limited clinical data.

What this study cannot tell us

Limited ALS-specific clinical data. Preclinical results are heterogeneous and model-dependent. Cannot definitively rule out benefit.

How to read the evidence

Comprehensive narrative review highlighting a critical safety concern. No ALS-specific RCT data to draw definitive conclusions.

When this study was published

Published in 2025.

The bigger picture

Not all neurodegenerative diseases will benefit from GLP-1 drugs. ALS's unique metabolic requirements (weight maintenance) may make these drugs inappropriate.

Questions still open

Could GLP-1 drugs be given at doses that provide neuroprotection without weight loss?
Would combining GLP-1 drugs with nutritional support mitigate the weight loss risk?
Are there GLP-1 drug analogs with neuroprotective but not anorexigenic effects?

Common questions

Should ALS patients take GLP-1 drugs?

Currently no. While GLP-1 drugs protect brain cells in other diseases, their weight loss effect may be harmful in ALS, where maintaining weight is linked to better survival. ALS-specific trials are needed first.

Why would a neuroprotective drug be harmful in ALS?

ALS is unique: patients who maintain their weight survive longer. GLP-1 drugs cause weight and muscle loss, which could accelerate decline even if they provide some nerve protection.

Read the original research

Targeting metabolic dysfunction in amyotrophic lateral sclerosis: therapeutic potential of GLP-1 receptor agonists.

Amyotrophic lateral sclerosis & frontotemporal degeneration, 1-27

View on PubMed ↗Publisher’s paper ↗

Citation

Helal, Mohamed Mohsen; Almosilhy, Nereen A; Abo-Elnour, Dina Essam; Jaffal, Rana Suhail Younis; Allam, Eman Gomaa; Almosilhy, Mohammed A; Batarseh, Suhel F; Meshref, Mostafa. (2026). Targeting metabolic dysfunction in amyotrophic lateral sclerosis: therapeutic potential of GLP-1 receptor agonists.. Amyotrophic lateral sclerosis & frontotemporal degeneration, 1-27. https://doi.org/10.1080/21678421.2026.2627901